The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biological correlates to support a clinical role for tagraxofusp, a novel targeted therapy directed to CD123, in combination with pomalidomide and dexamethasone, to target plasmacytoid dendritic cells in poor-risk patients with multiple myeloma.
 
Dharminder Chauhan
Stock and Other Ownership Interests - C4 Therapeutics
Consulting or Advisory Role - Stemline Therapeutics
 
Arghya Ray
No Relationships to Disclose
 
Yan Song
No Relationships to Disclose
 
Arturo Olguin
No Relationships to Disclose
 
Janice Chen
Employment - Stemline Therapeutics
Stock and Other Ownership Interests - Stemline Therapeutics
 
Christopher Brooks
No Relationships to Disclose
 
Tariq I. Mughal
No Relationships to Disclose
 
Paul G. Richardson
Consulting or Advisory Role - Celgene; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Oncopeptides; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Oncopeptides (Inst); Takeda (Inst)
 
Kenneth Carl Anderson
Stock and Other Ownership Interests - C4 Therapeutics; OncoPep
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen Oncology; Millennium; Precision Biosciences; Sanofi; Tolero Pharmaceuticals
Patents, Royalties, Other Intellectual Property - C4 Therapeutics; Oncopep